| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
African self-sufficiency in cancer control
|
Tawfiles, Davidi
|
|
|
26 |
7 |
p. e342
|
artikel
|
| 2 |
Analysis of drug consumption and expenditure of WHO essential medicines for cancer in 40 countries and regions between 2012 and 2022: a multinational drug use study
|
Jiao, Yuanshi
|
|
|
26 |
7 |
p. 877-886
|
artikel
|
| 3 |
2025 ASCO Annual Meeting
|
Gourd, Katherine
|
|
|
26 |
7 |
p. 841
|
artikel
|
| 4 |
Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study
|
Reddy, Che L
|
|
|
26 |
7 |
p. 924-935
|
artikel
|
| 5 |
Bridging borders for resilience in cancer control in the Middle East: a strategic alliance of Saudi Arabia, Qatar, and Jordan
|
Jafar, Hanan
|
|
|
26 |
7 |
p. e390-e397
|
artikel
|
| 6 |
Bridging borders in cancer control
|
Kutluk, Tezer
|
|
|
26 |
7 |
p. 835-836
|
artikel
|
| 7 |
Bridging tumour classification and treatment
|
Subbiah, Vivek
|
|
|
26 |
7 |
p. e343-e344
|
artikel
|
| 8 |
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
|
Agarwal, Neeraj
|
|
|
26 |
7 |
p. 860-876
|
artikel
|
| 9 |
Cancer care in Bahrain: progress, challenges, and strategic priorities
|
Hamadeh, Randah R
|
|
|
26 |
7 |
p. 830-831
|
artikel
|
| 10 |
Cancer control in the Middle East
|
Prowse, Jamie
|
|
|
26 |
7 |
p. 829-830
|
artikel
|
| 11 |
Cancer control in the Middle East: Kuwait perspective
|
Al-Naaimi, Meshari
|
|
|
26 |
7 |
p. 832-833
|
artikel
|
| 12 |
Cancer control in the United Arab Emirates
|
Mukherji, Deborah
|
|
|
26 |
7 |
p. e381-e389
|
artikel
|
| 13 |
Cancer took centre stage at the World Health Assembly
|
Adepoju, Paul
|
|
|
26 |
7 |
p. 839
|
artikel
|
| 14 |
Considerations for results of the patient-reported outcome analyses of the TALAPRO-2 trial
|
de Boissieu, Paul
|
|
|
26 |
7 |
p. e345
|
artikel
|
| 15 |
CONTACT-02 and beyond: rethinking immunotherapy strategies in metastatic prostate cancer
|
Mukherji, Deborah
|
|
|
26 |
7 |
p. 819-821
|
artikel
|
| 16 |
Correction to Lancet Oncol 2024; 25: 1614–24
|
|
|
|
26 |
7 |
p. e349
|
artikel
|
| 17 |
Correction to Lancet Oncol 2025; 26: 503–15
|
|
|
|
26 |
7 |
p. e349
|
artikel
|
| 18 |
Correction to Lancet Oncol 2025; 26: 571–82
|
|
|
|
26 |
7 |
p. e349
|
artikel
|
| 19 |
Correction to Lancet Oncol 2025; 26: 924–35
|
|
|
|
26 |
7 |
p. e349
|
artikel
|
| 20 |
Correction to Lancet Oncol 2025; 26: e46–54
|
|
|
|
26 |
7 |
p. e349
|
artikel
|
| 21 |
Correction to Lancet Oncol 2025; 26: e320–30
|
|
|
|
26 |
7 |
p. e349
|
artikel
|
| 22 |
Demystifying the WHO Model Lists of Essential Medicines for cancer care
|
Trapani, Dario
|
|
|
26 |
7 |
p. 821-823
|
artikel
|
| 23 |
England changes cervical cancer screening to every 5 years
|
Kirby, Tony
|
|
|
26 |
7 |
p. e350
|
artikel
|
| 24 |
Equity in cancer genomics in the UK: a cross-sectional analysis of a national cancer cohort
|
Nguyen, T
|
|
|
26 |
7 |
p. 971-980
|
artikel
|
| 25 |
First-in-world “Trojan horse” drug offered to multiple myeloma patients in England
|
Burki, Talha
|
|
|
26 |
7 |
p. e351
|
artikel
|
| 26 |
From conflict to care: rebuilding Syria's oncology infrastructure
|
Tawfiles, Davidi
|
|
|
26 |
7 |
p. 833-835
|
artikel
|
| 27 |
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
|
Fizazi, Karim
|
|
|
26 |
7 |
p. 948-959
|
artikel
|
| 28 |
Hormonal therapy for young-onset breast cancer: current understanding and lessons
|
Lévy, Christelle
|
|
|
26 |
7 |
p. 824-825
|
artikel
|
| 29 |
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
|
O’Brien, Katie M
|
|
|
26 |
7 |
p. 911-923
|
artikel
|
| 30 |
Improved recruitment equity in a UK cancer genomic testing programme
|
Evans, D Gareth
|
|
|
26 |
7 |
p. 827-829
|
artikel
|
| 31 |
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial
|
Tree, Alison C
|
|
|
26 |
7 |
p. 936-947
|
artikel
|
| 32 |
Millions could lose Medicaid coverage under US budget bill
|
Devi, Sharmila
|
|
|
26 |
7 |
p. 838
|
artikel
|
| 33 |
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial
|
Saito, Mitsue
|
|
|
26 |
7 |
p. 960-970
|
artikel
|
| 34 |
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy
|
Layman, Rachel M
|
|
|
26 |
7 |
p. e332-e333
|
artikel
|
| 35 |
Partial-breast irradiation: has the dust finally settled?
|
Krug, David
|
|
|
26 |
7 |
p. 823-824
|
artikel
|
| 36 |
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
|
Kirby, Anna M
|
|
|
26 |
7 |
p. 898-910
|
artikel
|
| 37 |
Politics and pharma: hurdles in UK science ambitions
|
The Lancet Oncology,
|
|
|
26 |
7 |
p. 817
|
artikel
|
| 38 |
Practice standard in British Colombia impacting opioid prescriptions for people with cancer
|
Burki, Talha
|
|
|
26 |
7 |
p. 837
|
artikel
|
| 39 |
Qatar national cancer care and research: pioneering strategies for global health excellence
|
Al-Thani, Mohammed Bin Hamed
|
|
|
26 |
7 |
p. e369-e380
|
artikel
|
| 40 |
RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
|
Vis, André N
|
|
|
26 |
7 |
p. e334
|
artikel
|
| 41 |
RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
|
Aluwini, Shafak
|
|
|
26 |
7 |
p. e335
|
artikel
|
| 42 |
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
|
de Velasco, Guillermo
|
|
|
26 |
7 |
p. e346
|
artikel
|
| 43 |
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
|
Larcher, Alessandro
|
|
|
26 |
7 |
p. e347
|
artikel
|
| 44 |
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply
|
Srinivasan, Ramaprasad
|
|
|
26 |
7 |
p. e348
|
artikel
|
| 45 |
Rwanda provides free treatment to all cancer patients
|
Nakkazi, Esther
|
|
|
26 |
7 |
p. 840
|
artikel
|
| 46 |
SANO trial: innovations, risks, and unanswered questions
|
Kapoor, Akhil
|
|
|
26 |
7 |
p. e336
|
artikel
|
| 47 |
SANO trial: innovations, risks, and unanswered questions
|
Markar, Sheraz R
|
|
|
26 |
7 |
p. e338
|
artikel
|
| 48 |
SANO trial: innovations, risks, and unanswered questions
|
Housman, Brian
|
|
|
26 |
7 |
p. e337
|
artikel
|
| 49 |
SANO trial: innovations, risks, and unanswered questions
|
Oruç, Ahmet
|
|
|
26 |
7 |
p. e339
|
artikel
|
| 50 |
SANO trial: innovations, risks, and unanswered questions – Authors' reply
|
van der Wilk, Berend J
|
|
|
26 |
7 |
p. e340-e341
|
artikel
|
| 51 |
Setting the PACE for prostate radiotherapy
|
Nickols, Nicholas G
|
|
|
26 |
7 |
p. 826-827
|
artikel
|
| 52 |
Solutions for tackling the global surgery crisis in west Africa
|
Cheng, Leo
|
|
|
26 |
7 |
p. 843-845
|
artikel
|
| 53 |
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
|
Zhou, Caicun
|
|
|
26 |
7 |
p. 887-897
|
artikel
|
| 54 |
The CANDLE mission begins in EU countries
|
Das, Manjulika
|
|
|
26 |
7 |
p. 842
|
artikel
|
| 55 |
Towards a comprehensive cancer control policy in Saudi Arabia
|
Alessy, Saleh A
|
|
|
26 |
7 |
p. e360-e368
|
artikel
|
| 56 |
Transforming cancer care in Jordan: a 10-year comprehensive patient-centred strategy guided by local experts
|
Abdel-Razeq, Hikmat
|
|
|
26 |
7 |
p. e352-e359
|
artikel
|
| 57 |
You are her son, not her doctor
|
Eyrich, Nicholas W
|
|
|
26 |
7 |
p. 846
|
artikel
|
| 58 |
Zanidatamab, a bispecific monoclonal antibody for HER2-positive gastro-oesophageal adenocarcinoma patients: a new hope?
|
Coutzac, Clélia
|
|
|
26 |
7 |
p. 818-819
|
artikel
|
| 59 |
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
|
Elimova, Elena
|
|
|
26 |
7 |
p. 847-859
|
artikel
|
Tijdschrift beschrijving